{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-042392","form_type":"8-K","ticker":"DSGN","cik":"0001807120","company_name":"Design Therapeutics, Inc.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.335219+00:00","generated_at":"2026-06-11T12:19:22.021771+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Design Therapeutics Reports Q2 2023 Results, Pipeline Progress with DT-216 and DT-168","bullets":["Initial Phase 1 data for DT-216 in Friedreich Ataxia showed significant dose-related FXN mRNA increase in skeletal muscle (p<0.05)","DT-216 Phase 1 MAD trial resumed in H2 2024 with improved formulation, data expected H1 2025","IND submission for DT-168 for Fuchs Endothelial Corneal Dystrophy on track for H2 2023","Cash and securities of $303.1M as of June 30, 2023, expected to fund operations through 2026","Net loss of $19.9M for Q2 2023; R&D expenses $17.1M, G&A $5.5M"],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-042392","json":"https://secwatch.observer/filing/0000950170-23-042392.json","markdown":"https://secwatch.observer/filing/0000950170-23-042392.md","text":"https://secwatch.observer/filing/0000950170-23-042392.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1807120/000095017023042392/0000950170-23-042392-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1807120/000095017023042392/dsgn-20230814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T12:19:22.021771+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"95a327edb199ec7db0bb8dd2b8f64532c4066ad9","claim":"Design Therapeutics, Inc. reported the quarter ended June 30, 2023 results: net income Net loss was $19.9 million for the quarter ended June 30, 2023..","evidence_excerpt":"Net loss was $19.9 million for the quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1807120/000095017023042392/0000950170-23-042392-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Net income","value":"Net loss was $19.9 million for the quarter ended June 30, 2023."},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}